v3.26.1
SEGMENT INFORMATION - Company`S Segment, Including Segment Expenses, and A Reconciliation to Net Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total revenues $ 401,251   $ 611,091   $ 1,132,054 $ 1,355,947
Segment expenses and other segment items            
Cost of sales (excluding amortization of in-licensed rights) 149,385   152,558   258,153 290,122
Selling, general and administrative- other (excluding non-cash items) 107,600   137,897   216,551 271,526
Loss (gain) on strategic investments (448)   36,721   (2,160) (54,007)
Interest expense (21,508)   (5,228)   (43,221) (9,731)
Interest income 6,207   5,254   12,567 15,444
Income tax expense (benefit) 3,141   (43,254)   15,356 20,736
Depreciation and amortization expense         21,003 20,818
Stock-based compensation expense         53,871 78,453
Litigation contingency charge 39,000   0   39,000 0
Net Income (Loss) (4,890) $ 330,959 196,892 $ (447,508) 326,069 (250,616)
Reconciliation of profit or loss            
Adjustments and reconciling items 0   0   0 0
Net (loss) income - basic (4,890) $ 330,959 196,892 $ (447,508) 326,069 (250,616)
Operating Segments [Member]            
Segment Reporting [Line Items]            
Total revenues 401,251   611,091   1,132,054 1,355,947
Segment expenses and other segment items            
Cost of sales (excluding amortization of in-licensed rights) 149,385   152,558   258,153 290,122
Compensation and other personnel expenses 60,725   89,839   122,655 182,923
Up-front and Collaboration License Fees 0   0   50,000 583,787
Manufacturing expenses 1,837   80,685   21,595 148,150
Clinical trial expenses 23,102   33,511   41,406 66,658
Facility- and technology-related expenses (excluding depreciation and amortization) 23,890   28,580   46,832 56,237
Research and development- other (excluding non-cash items) [1] 19,847   31,843   38,518 60,314
Selling, general and administrative- other (excluding non-cash items) [2] 42,462   56,322   82,655 107,464
Roche Collaboration Reimbursement (7,169)   (25,689)   (15,358) (54,170)
Other segment items [3] (709)   (1,314)   (2,515) (3,223)
Loss (gain) on strategic investments 448   (36,721)   2,160 54,007
Interest expense 21,508   5,228   43,221 9,731
Interest income (6,207)   (5,254)   (12,567) (15,444)
Income tax expense (benefit) 3,141   (43,254)   15,356 20,736
Depreciation and amortization expense 10,409   10,840   21,003 20,818
Stock-based compensation expense 24,472   37,025   53,871 78,453
Litigation contingency charge 39,000   0   39,000 0
Net Income (Loss) (4,890)   196,892   326,069 (250,616)
Reconciliation of profit or loss            
Net (loss) income - basic $ (4,890)   $ 196,892   $ 326,069 $ (250,616)
[1] Research and development-other includes professional services, pre-clinical expenses and research and other expenses.
[2] Selling, general and administrative-other includes professional services and other expenses.
[3] Other segment items included in segment net (loss) income include accretion of investment discount, net and other, net, as well as items separately presented and not defined as significant expenses below.

Significant expense categories that are regularly provided to the CODM include cost of sales (excluding amortization of in-licensed rights), compensation and other personnel expenses, up-front and collaboration license expenses, manufacturing expenses, clinical trial expenses, facility- and technology-related expenses, research and development- other and selling, general and administrative- other. The other expense or income information are other segment items and include separate presentation of loss (gain) on strategic investments, interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense and litigation contingency charge, which are included in the measure of segment net (loss) income, but are not significant segment expenses.

Assets provided to the CODM for the single segment are consistent with those reported on the unaudited condensed consolidated balance sheets.